Table 2 Baseline characteristics
Characteristics | Number of the patients | ||||
|---|---|---|---|---|---|
Losartan | Valsartan | Telmisartan | Candesartan | Olmesartan | |
Total number of patients | 214 | 266 | 185 | 458 | 192 |
Men | 113 | 172 | 113 | 272 | 127 |
Medical History | |||||
Cerebrovascular disease | 61 | 86 | 63 | 135 | 47 |
Ischemic heart disease | 70 | 93 | 69 | 168 | 50 |
Other heart disease | 54 | 75 | 43 | 118 | 49 |
Malignant neoplasm | 104 | 136 | 87 | 252 | 105 |
Thyroid disease | 76 | 78 | 67 | 149 | 69 |
Rheumatoid disease | 56 | 33 | 35 | 68 | 19 |
Liver disease | 111 | 148 | 99 | 265 | 104 |
Kidney disease | 127 | 132 | 116 | 226 | 90 |
Hyperlipidemia | 128 | 167 | 112 | 287 | 113 |
Proteinuria | 96 | 98 | 71 | 170 | 73 |
Current Medication | |||||
Oral hypoglycemic drugs | 46 | 78 | 62 | 129 | 69 |
Immnosupressive drugs | 16 | 6 | 6 | 11 | 5 |
Lipid-lowering drugs | 86 | 99 | 65 | 183 | 69 |
Statin | 69 | 75 | 53 | 134 | 52 |
Fibrate | 6 | 11 | 6 | 26 | 8 |
Other lipid-lowering drugs | 21 | 18 | 13 | 42 | 13 |
Thyroid drugs | 8 | 5 | 6 | 16 | 2 |
Antipsychotic drugs | 22 | 11 | 6 | 23 | 7 |
Antithrombotic drugs | 72 | 87 | 63 | 133 | 44 |
Chemotherapeutics drugs | 3 | 9 | 4 | 21 | 4 |
Liver disease therapeutics | 15 | 10 | 4 | 15 | 13 |
CKD therapeutic drugs | 6 | 0 | 0 | 2 | 0 |
Steroids | 40 | 23 | 24 | 49 | 13 |
NSAIDs | 82 | 96 | 57 | 132 | 52 |
Proton pump inhibitors | 47 | 34 | 35 | 73 | 35 |
H2 blockers | 48 | 38 | 26 | 75 | 23 |